Opus Genetics (IRD) Liabilities and Shareholders Equity (2010 - 2026)

Opus Genetics (IRD) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $66.8 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 38.66% year-over-year to $66.8 million in Q1 2026; TTM through Mar 2026 was $191.8 million, a 12.67% increase from a year earlier, with the FY2025 full-year figure at $50.2 million, up 36.3% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $66.8 million, up from $50.2 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for IRD reached as high as $66.8 million in Q1 2026 and fell as low as $14.6 million in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $41.9 million across 5 years, with a median of $44.8 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 37.22% in 2022 and soared 271.99% in 2023, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $49.0 million in 2022, then rose by 10.12% to $53.9 million in 2023, then sank by 31.67% to $36.9 million in 2024, then jumped by 36.3% to $50.2 million in 2025, then soared by 32.93% to $66.8 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $66.8 million in Q1 2026, $50.2 million in Q4 2025, and $36.1 million in Q3 2025.